PT3122426T - Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio - Google Patents
Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénioInfo
- Publication number
- PT3122426T PT3122426T PT157693946T PT15769394T PT3122426T PT 3122426 T PT3122426 T PT 3122426T PT 157693946 T PT157693946 T PT 157693946T PT 15769394 T PT15769394 T PT 15769394T PT 3122426 T PT3122426 T PT 3122426T
- Authority
- PT
- Portugal
- Prior art keywords
- treating cancer
- estrogen receptor
- receptor modulators
- selective estrogen
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461971627P | 2014-03-28 | 2014-03-28 | |
US14/512,061 US9421264B2 (en) | 2014-03-28 | 2014-10-10 | Method of treating cancer using selective estrogen receptor modulators |
US201562129379P | 2015-03-06 | 2015-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3122426T true PT3122426T (pt) | 2023-02-28 |
Family
ID=54196487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT157693946T PT3122426T (pt) | 2014-03-28 | 2015-03-28 | Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio |
Country Status (16)
Country | Link |
---|---|
US (4) | US10420734B2 (pt) |
EP (3) | EP3834824A1 (pt) |
CA (1) | CA2943611A1 (pt) |
DK (1) | DK3122426T3 (pt) |
ES (1) | ES2939940T3 (pt) |
FI (2) | FI3122426T3 (pt) |
FR (1) | FR24C1007I1 (pt) |
HR (1) | HRP20230365T1 (pt) |
HU (2) | HUE061499T2 (pt) |
LT (1) | LT3122426T (pt) |
NO (1) | NO2024007I1 (pt) |
PL (1) | PL3122426T3 (pt) |
PT (1) | PT3122426T (pt) |
RS (1) | RS64115B1 (pt) |
SI (1) | SI3122426T1 (pt) |
WO (1) | WO2015149045A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP3834824A1 (en) | 2014-03-28 | 2021-06-16 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
IL310069A (en) * | 2015-04-29 | 2024-03-01 | Radius Pharmaceuticals Inc | Cancer treatment methods |
US10118910B2 (en) | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
WO2018071440A1 (en) | 2016-10-11 | 2018-04-19 | Duke University | Treatment of breast cancer |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
JP2020507566A (ja) | 2017-02-10 | 2020-03-12 | ジー1 セラピューティクス, インコーポレイテッド | ベンゾチオフェンエストロゲン受容体モジュレーター |
CN117771239A (zh) * | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
CA3109090A1 (en) * | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
JP2023516291A (ja) * | 2020-03-06 | 2023-04-19 | オレマ ファーマシューティカルズ インク. | エストロゲン受容体関連疾患の治療方法 |
WO2022020605A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Treatment of metastasized estrogen receptor positive breast cancer |
WO2023172909A1 (en) * | 2022-03-08 | 2023-09-14 | Context Biopharma Inc. | Compositions comprising anti-progestins and selective estrogen receptor modulators and methods of using the same |
WO2023224961A1 (en) | 2022-05-16 | 2023-11-23 | Exelixis, Inc. | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
GB1547758A (en) | 1975-07-29 | 1979-06-27 | Shell Int Research | Herbicidal composition |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
DE2909754A1 (de) | 1979-03-13 | 1980-09-18 | Thomae Gmbh Dr K | Neue benzofuran- und benzothiophenderivate, deren herstellung und deren verwendung als arzneimittel |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
EP0226508A1 (fr) | 1985-12-02 | 1987-06-24 | Sanofi | Dérivés de l'indolo(3,2-c)quinoléine, leur procédé de préparation et leur activité antitumorale |
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
JPH07121931B2 (ja) | 1989-06-22 | 1995-12-25 | キッセイ薬品工業株式会社 | ベンゾ〔b〕フラン誘導体 |
US5166170A (en) | 1989-07-03 | 1992-11-24 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
DE4420644A1 (de) | 1994-06-14 | 1995-12-21 | Basf Ag | Farbige Metalloxidpigmente enthaltende Kugelschreiberpasten |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51652C2 (uk) | 1995-06-08 | 2002-12-16 | Новартіс Аг | Спосіб гідрування імінів |
ATE206701T1 (de) | 1996-04-19 | 2001-10-15 | American Home Prod | Östrogene verbindungen |
DE69709752T2 (de) | 1996-06-27 | 2002-07-18 | Ligand Pharm Inc | Androgen rezeptor modulator verbindungen und verfahren |
FR2770842B1 (fr) | 1997-11-13 | 1999-12-17 | Oreal | Nouveaux composes derives de n-aryl 2-hydroxy alkylamides |
WO2001032631A2 (en) | 1999-10-29 | 2001-05-10 | Rutgers, The State University Of New Jerey | Heterocyclic cytotoxic agents |
US6544553B1 (en) | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
WO2001049673A2 (en) | 1999-12-30 | 2001-07-12 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
AU2991301A (en) | 2000-01-28 | 2001-08-07 | Endorecherche Inc. | Selective estrogen receptor modulators in combination with estrogens |
US20010044431A1 (en) | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
ES2252273T3 (es) | 2000-08-23 | 2006-05-16 | Akzo Nobel N.V. | Derivados de 10-aril-11h-benzo(b)fluoreno y analogos destinados para una utilizacion medicinal. |
PT1401801E (pt) | 2000-08-24 | 2007-02-28 | Univ Tennessee Res Foundation | Modulares selectivos de receptor de androgénio e métodos para a sua utilização |
IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
US6670386B2 (en) | 2001-07-31 | 2003-12-30 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
CA2456150A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
CN1633287A (zh) | 2002-02-15 | 2005-06-29 | 恩多研究公司 | 联苯衍生物及其作为抗雄激素试剂的应用 |
PT1501819E (pt) | 2002-04-24 | 2010-11-11 | Merck Sharp & Dohme | Moduladores dos receptores de estrogéneo |
TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
TW200307553A (en) | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
JP2006513159A (ja) | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
UA79504C2 (en) | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
JP2006523196A (ja) | 2003-03-11 | 2006-10-12 | ニューロサーチ、アクティーゼルスカブ | 新規kcnqチャネルを調節する化合物及びその医薬用途 |
JP2007505164A (ja) | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての1−アミノナフタレン類 |
WO2005000795A2 (en) | 2003-06-10 | 2005-01-06 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
EP1643978A1 (en) | 2003-07-04 | 2006-04-12 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
JP2007521328A (ja) | 2003-11-20 | 2007-08-02 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲン受容体モジュレーター |
AU2003297904A1 (en) | 2003-12-12 | 2005-07-14 | University Of Maryland, Baltimore | Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain |
UA85862C2 (uk) | 2004-01-22 | 2009-03-10 | Елі Ліллі Енд Компані | Селективні модулятори рецепторів естрогену для лікування вазомоторних симптомів |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
EP1725522B1 (en) | 2004-03-03 | 2014-09-10 | GlaxoSmithKline LLC | Aniline derivatives as selective androgen receptor modulators |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US20080125399A1 (en) | 2004-04-08 | 2008-05-29 | Jiabing Wang | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators |
TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
CN1980917B (zh) | 2004-05-03 | 2014-02-12 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂(sarms)的新的吲哚衍生物 |
US20080045504A1 (en) | 2004-05-11 | 2008-02-21 | Pfizer Products Inc. | Benzonitrile Derivatives to Treat Musculoskeletal Frailty |
CN101072780B (zh) | 2004-09-20 | 2010-06-23 | 詹森药业有限公司 | 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物 |
WO2006039243A1 (en) | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica N.V. | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
WO2006044707A1 (en) | 2004-10-13 | 2006-04-27 | Smithkline Beecham Corporation | Chemical compounds |
CA2585276A1 (en) | 2004-10-29 | 2006-06-08 | Merck & Co., Inc. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
CA2587678C (en) | 2004-11-16 | 2013-05-21 | Janssen Pharmaceutica N.V. | Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms) |
JP5203712B2 (ja) | 2005-01-10 | 2013-06-05 | アカディア ファーマシューティカルズ インコーポレイテッド | 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体 |
EP1871379A4 (en) | 2005-04-15 | 2010-06-02 | Glaxosmithkline Llc | CYANOARYLAMINE |
PL1891038T3 (pl) | 2005-05-13 | 2009-04-30 | Lilly Co Eli | Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego |
WO2006133216A2 (en) | 2005-06-06 | 2006-12-14 | Smithkline Beecham Corporation | 4-substituted arylamine derivatives and their use in pharmaceutical compositions |
US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
EP1902026B1 (en) | 2005-06-24 | 2010-02-17 | Eli Lilly And Company | Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm) |
AR057656A1 (es) | 2005-07-01 | 2007-12-12 | Ligand Pharm Inc | Compuestos moduladores de receptores de androgeno y metodods relacionados |
JP5070054B2 (ja) | 2005-08-01 | 2012-11-07 | 武田薬品工業株式会社 | 環状アミン化合物 |
JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Grk阻害剤からなる強心薬 |
TW200730505A (en) | 2005-12-07 | 2007-08-16 | Merck & Co Inc | Polymorphs of an androgen receptor modulator |
EA015542B1 (ru) | 2006-01-24 | 2011-08-30 | Янссен Фармацевтика Н.В. | Новые 2-замещённые бензимидазолы в качестве селективных модуляторов рецептора андрогена (sarms) |
JP5373405B2 (ja) | 2006-03-03 | 2013-12-18 | オリオン コーポレーション | 選択的アンドロゲン受容体モジュレーター |
US8933130B2 (en) | 2006-06-23 | 2015-01-13 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
CA2658394C (en) | 2006-07-12 | 2016-08-16 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
EP2041077A2 (en) | 2006-07-19 | 2009-04-01 | The Ohio State University Research Foundation | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
DK2054049T3 (en) | 2006-08-24 | 2016-08-01 | Univ Tennessee Res Found | SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF |
WO2008042571A2 (en) | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
WO2008128100A1 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of California | Small-molecule inhibitors of the androgen receptor |
WO2008156613A1 (en) | 2007-06-12 | 2008-12-24 | Schering Corporation | Histone h2ax (hh2ax) biomarker for fti sensitivity |
KR101089045B1 (ko) | 2007-06-28 | 2011-12-02 | (주)바이오니아 | 핵산증폭반응 산물의 실시간 모니터링장치 |
NZ583624A (en) | 2007-08-07 | 2012-06-29 | Takeda Pharmaceutical | Pyrrolidin-2-one derivatives as androgen receptor modulator |
US8354446B2 (en) | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
WO2009105214A2 (en) | 2008-02-22 | 2009-08-27 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
US20110124617A1 (en) | 2008-05-09 | 2011-05-26 | Lyttle C Richard | Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent |
ES2396612T3 (es) | 2008-05-16 | 2013-02-22 | Eli Lilly & Company | Tetrahidrociclopenta[b]indoles como moduladores del receptor de andrógenos |
GB2475183B (en) | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
CN116343705A (zh) | 2009-10-16 | 2023-06-27 | 株式会社半导体能源研究所 | 显示设备 |
JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
LT2568806T (lt) | 2010-05-12 | 2016-09-26 | Radius Health, Inc. | Terapiniai režimai |
JP5965909B2 (ja) | 2010-09-28 | 2016-08-10 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
GB201217439D0 (en) | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
US9408847B2 (en) | 2012-11-28 | 2016-08-09 | Novartis Ag | Combination therapy |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP3834824A1 (en) | 2014-03-28 | 2021-06-16 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
IL310069A (en) | 2015-04-29 | 2024-03-01 | Radius Pharmaceuticals Inc | Cancer treatment methods |
-
2015
- 2015-03-28 EP EP21151737.0A patent/EP3834824A1/en active Pending
- 2015-03-28 PT PT157693946T patent/PT3122426T/pt unknown
- 2015-03-28 WO PCT/US2015/023216 patent/WO2015149045A1/en active Application Filing
- 2015-03-28 ES ES15769394T patent/ES2939940T3/es active Active
- 2015-03-28 EP EP21215140.1A patent/EP4035664A3/en active Pending
- 2015-03-28 DK DK15769394.6T patent/DK3122426T3/da active
- 2015-03-28 CA CA2943611A patent/CA2943611A1/en active Pending
- 2015-03-28 HR HRP20230365TT patent/HRP20230365T1/hr unknown
- 2015-03-28 LT LTEPPCT/US2015/023216T patent/LT3122426T/lt unknown
- 2015-03-28 SI SI201531925T patent/SI3122426T1/sl unknown
- 2015-03-28 HU HUE15769394A patent/HUE061499T2/hu unknown
- 2015-03-28 RS RS20230271A patent/RS64115B1/sr unknown
- 2015-03-28 EP EP15769394.6A patent/EP3122426B1/en active Active
- 2015-03-28 FI FIEP15769394.6T patent/FI3122426T3/fi active
- 2015-03-28 PL PL15769394.6T patent/PL3122426T3/pl unknown
- 2015-03-28 US US15/129,197 patent/US10420734B2/en active Active
-
2019
- 2019-08-23 US US16/549,828 patent/US20200009084A1/en not_active Abandoned
-
2021
- 2021-12-22 US US17/558,731 patent/US11779552B2/en active Active
-
2023
- 2023-08-29 US US18/457,567 patent/US20230398085A1/en active Pending
-
2024
- 2024-02-20 HU HUS2400002C patent/HUS2400002I1/hu unknown
- 2024-02-21 NO NO2024007C patent/NO2024007I1/no unknown
- 2024-02-26 FR FR24C1007C patent/FR24C1007I1/fr active Active
- 2024-03-06 FI FIC20240005C patent/FIC20240005I1/fi unknown
Also Published As
Publication number | Publication date |
---|---|
EP3122426B1 (en) | 2023-01-18 |
US20230398085A1 (en) | 2023-12-14 |
DK3122426T3 (da) | 2023-04-03 |
CA2943611A1 (en) | 2015-10-01 |
SI3122426T1 (sl) | 2023-04-28 |
PL3122426T3 (pl) | 2023-05-15 |
HRP20230365T1 (hr) | 2023-06-23 |
EP4035664A3 (en) | 2022-11-30 |
NO2024007I1 (no) | 2024-02-21 |
US20220110893A1 (en) | 2022-04-14 |
WO2015149045A1 (en) | 2015-10-01 |
FIC20240005I1 (fi) | 2024-03-06 |
FR24C1007I1 (fr) | 2024-04-19 |
EP4035664A2 (en) | 2022-08-03 |
ES2939940T3 (es) | 2023-04-28 |
RS64115B1 (sr) | 2023-04-28 |
EP3122426A4 (en) | 2017-11-29 |
HUE061499T2 (hu) | 2023-07-28 |
HUS2400002I1 (hu) | 2024-03-28 |
EP3834824A1 (en) | 2021-06-16 |
US20170202823A1 (en) | 2017-07-20 |
US20200009084A1 (en) | 2020-01-09 |
US10420734B2 (en) | 2019-09-24 |
US11779552B2 (en) | 2023-10-10 |
LT3122426T (lt) | 2023-03-10 |
FI3122426T3 (fi) | 2023-03-31 |
EP3122426A1 (en) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2400002I1 (hu) | Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával | |
IL283700A (en) | System and method for secure communication | |
IL304252A (en) | Cancer treatment methods | |
IL289947A (en) | A method for treating cancer | |
HK1248252A1 (zh) | 使用抗cd79b免疫偶聯物的方法 | |
IL265217A (en) | Modulators of glucocorticoid receptors and their use in the treatment of pancreatic cancer | |
EP3110509A4 (en) | Method for treating cancer | |
SG11201607130RA (en) | Combination method for treatment of cancer | |
HK1254258A1 (zh) | 使用阿吡莫德治療癌症的方法 | |
NO20161459A1 (en) | Method for treatment of underground reservoirs | |
PL3397002T3 (pl) | Sposób i urządzenie do sterowania ruchem | |
IL246558A0 (en) | New methods of cancer treatment | |
IL249203B (en) | Androgen receptor modulators and methods of using them | |
GB2543359B (en) | Methods and apparatus for secure communication | |
GB201510197D0 (en) | Method of treating ovarian cancer | |
GB201405024D0 (en) | Methods and apparatus for enabling communication | |
GB201405015D0 (en) | Methods and apparatus for enabling communication |